GOSS vs. ELVN, NAGE, AUPH, WVE, SYRE, PAHC, CRMD, RCUS, COLL, and ABCL
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Enliven Therapeutics (ELVN), Niagen Bioscience (NAGE), Aurinia Pharmaceuticals (AUPH), Wave Life Sciences (WVE), Spyre Therapeutics (SYRE), Phibro Animal Health (PAHC), CorMedix (CRMD), Arcus Biosciences (RCUS), Collegium Pharmaceutical (COLL), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.
Gossamer Bio vs. Its Competitors
Enliven Therapeutics (NASDAQ:ELVN) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.
Gossamer Bio has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Enliven Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -41.12%. Enliven Therapeutics' return on equity of -31.84% beat Gossamer Bio's return on equity.
95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 25.9% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Enliven Therapeutics presently has a consensus target price of $39.60, indicating a potential upside of 83.59%. Gossamer Bio has a consensus target price of $7.75, indicating a potential upside of 500.78%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Enliven Therapeutics.
In the previous week, Enliven Therapeutics had 21 more articles in the media than Gossamer Bio. MarketBeat recorded 22 mentions for Enliven Therapeutics and 1 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.17 beat Enliven Therapeutics' score of 0.58 indicating that Gossamer Bio is being referred to more favorably in the news media.
Enliven Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500.
Gossamer Bio received 142 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 88.24% of users gave Enliven Therapeutics an outperform vote while only 67.09% of users gave Gossamer Bio an outperform vote.
Summary
Gossamer Bio beats Enliven Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GOSS) was last updated on 6/19/2025 by MarketBeat.com Staff
Buy GOSS Stock Free GOSS Stock Alerts